The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: A controlled clinical pilot study

Ophthalmology

Volumn 109, Issue 5, 2002, Pages 845-850

  Hillenkamp, Jost ^a   Reinhard, Thomas ^a   Ross, Rudolf S ^b   Böhringer, Daniel ^a   Cartsburg, Olaf ^a   Roggendorf, Michael ^b   De Clercq, Erik ^c   Godehardt, Erhard ^a   Sundmacher, Rainer ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CYCLOSPORIN A; EYE DROPS;

ADENOVIRUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA OPACITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KERATITIS; KERATOCONJUNCTIVITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN TOXICITY; TREATMENT OUTCOME;

ACUTE DISEASE; ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CONJUNCTIVA; CYCLOSPORINE; CYTOSINE; DNA PRIMERS; DNA, VIRAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, VIRAL; EYELIDS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOCONJUNCTIVITIS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; SAFETY;

EID: 0036234272     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)00992-2     Document Type: Article

References (28)

1. Keratitis punctata superficialis
2. New type of APC virus from epidemic keratoconjunctivitis
3. Follicular conjunctivitis
4. Lokales cyclosporin A bei nummuli nach keratoconjunctivitis epidemica. Eine pilotstudie
5. Pathologisch-anatomischer befund einer hornhaut bei keratitis epidemica
6. Corneal histology after epidemic keratoconjunctivitis
7. Zum problem der rezidivierenden und persistierenden nummuli nach keratoconjunctivitis epidemica
8. Epidemiology of epidemic keratoconjunctivitis
9. Therapeutic potential of HPMPC as an antiviral drug
10. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model
11. Treatment of adenoviral conjunctivitis with topical cidofovir
12. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporin A: A controlled clinical pilot study
13. Cyclosporin A in patients receiving renal allografts from cadaver donors
14. Immunological analysis and treatment of Mooren's ulcer with cyclosporin A applied topically
15. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis
16. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis
17. Topical cyclosporin A in the treatment of anterior segment inflammatory disease
18. Topical cyclosporin A in Thygeson's superficial punctate keratitis
19. Trifluorthymidinprophylaxe bei der steroid-therapie herpetischer keratouveitiden
20. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
21. Use of polymerase chain amplification reaction for the detection of adenoviruses in ocular swab specimens
22. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′ nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro
23. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model
24. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model
25. Ocular side-effects from systemic HPMPC (cidofovir) for a non-ocular cytomegalovirus infection
26. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention
27. Effects of topical and subconjunctival cidofovir (HPMPC) in an animal model
28. An ocular model of adenovirus type 5 infection in the NZ rabbit